Clinical Trials Sponsored by Protgen Ltd

Total 17001 results

Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Breast Cancer

China
Protgen Ltd

Unknown

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Liver Cancer

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer

Colorectal Cancer

China
Protgen Ltd

Unknown

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Pancreatic Cancer

China
Protgen Ltd

Completed

Single-dose Escalation Trial of M2ES in Healthy Volunteer

Cancer
Protgen Ltd

Unknown

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
ProGen. Co., Ltd.

Recruiting

A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers

Healthy | Overweight

Korea, Republic of
Prothena Biosciences Ltd.

Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

AL Amyloidosis

United States, Spain, Australia, Italy, Germany, Austria, Greece, France, Israel, United Kingdom
Prothena Biosciences Ltd.

Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)

Primary Systemic (AL) Amyloidosis

United States, Spain, Israel, Canada, Poland, Netherlands, France, Germany, United Kingdom, Belgium, Denmark, Greece, Australia, Austria, Italy
Prothena Biosciences Ltd.

Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Primary Amyloidosis

United States
Prothena Biosciences Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

Light Chain (AL) Amyloidosis

United States, Korea, Republic of, Australia, Denmark, France, Italy, Spain, Israel, Taiwan, Austria, Canada, Czechia, Germany, Greece, Hungary, Japan, Netherlands, Poland, Portugal, Turkey, United Kingdom, Belgium, Ireland
Prothena Biosciences Ltd.

Terminated

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis (OLE)

AL Amyloidosis

United States
Prothena Biosciences Ltd.

Completed

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis (PRONTO)

AL Amyloidosis

United States, Spain, Australia, Germany, United Kingdom, France, Greece, Israel, Italy, Austria
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
UroGen Pharma Ltd.

Completed

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC (OPTIMA)

Carcinoma of Urinary Bladder, Superficial

Israel, Spain, Italy, Switzerland
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
UroGen Pharma Ltd.

Terminated

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Overactive Bladder

Israel
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
UroGen Pharma Ltd.

Withdrawn

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") (INTIMO2)

Overactive Bladder

Israel
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
UroGen Pharma Ltd.

Withdrawn

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG)

Non Muscle Invasive Bladder Cancer

Israel
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
UroGen Pharma Ltd.

Completed

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Interstitial Cystitis | IC

Israel
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
Progen Pharmaceuticals

Completed

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Progen Pharmaceuticals

Terminated

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma (PATHWAY)

Cancer | Hepatocellular Carcinoma | Primary Liver Cancer | Liver Cancer | Hepatoma

Hong Kong, Singapore, United States, Australia, Canada, Italy, Malaysia, Spain, Taiwan, Thailand
Progen Pharmaceuticals

Completed

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Cancer

United States
Progen Pharmaceuticals

Completed

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Age Related Macular Degeneration

United States, Mexico, Russian Federation
UroGen Pharma Ltd.
Tanner Pharma Group

Available

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent
Jonsson Comprehensive Cancer Center
UroGen Pharma Ltd.

No longer available

Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma

Urothelial Carcinoma Ureteral Location

United States
Proteon Therapeutics

Withdrawn

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Peripheral Artery Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease (PRT-201-102)

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Chronic Kidney Disease

United States, Canada
Proteon Therapeutics

Completed

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Peripheral Artery Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
Protein Supplies SL

Completed

Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment

Inflammation | Obesity

Spain
Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States

Clinical Trials Sponsored by Protgen Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations